Over the past four years, one question has repeatedly surfaced within the UK hemp and CBD industry: how did certain CBD products, including those linked to Pureis, come to be included on the Food Standards Agency CBD Public List despite clear requirements that products had to be on the market before 13 February 2020? This article examines the evidence, correspondence, FOI disclosures, and complaint files surrounding that question.

When a fixed regulatory deadline meets withheld evidence and shifting interpretations, questions follow. This open letter examines how the UK Food Standards Agency has applied its CBD novel foods rules—and whether those decisions can be properly scrutinised.

With a proposed UK–EU Sanitary and Phytosanitary (SPS) agreement potentially aligning food regulations, questions are emerging about where regulatory authority ultimately sits.

To me, both May’s and Atkins’ paths highlighted what I think is the biggest conflict... the dinner conversation.

This isn’t just about hemp or novel foods — it’s about the entire framework of cannabis regulation in the UK, how that framework was shaped, and who shaped it.

This is bigger than novel foods. This is about regulatory manipulation and undeclared conflicts of a senior Civil Servant when investigating a complaint that was made in the public interest.

How did 'Skunk' end up on an MHRA Yellow Card list meant for medicines and vaccines? And why does the timeline perfectly align with GW Pharm